(0.16%) 5 311.68 points
(-0.38%) 39 852 points
(0.65%) 16 794 points
(-0.30%) $79.82
(4.68%) $2.75
(0.97%) $2 440.80
(4.13%) $32.55
(-2.39%) $1 063.90
(0.06%) $0.920
(0.13%) $10.69
(-0.05%) $0.787
(-0.41%) $90.59
Live Chart Being Loaded With Signals
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer...
Stats | |
---|---|
Today's Volume | 1.19M |
Average Volume | 6.68M |
Market Cap | 150.38M |
EPS | $0 ( 2024-05-14 ) |
Next earnings date | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 9.19 |
ATR14 | $0.00600 (0.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-15 | Young Matthew P. | Buy | 38 000 | Stock Option (Right to Buy) |
2024-05-15 | Su Zhen | Buy | 38 000 | Stock Option (Right to Buy) |
2024-05-15 | Mohindru Mani | Buy | 38 000 | Stock Option (Right to Buy) |
2024-05-15 | Meyers James R | Buy | 38 000 | Stock Option (Right to Buy) |
2024-05-15 | Jones Elaine V | Buy | 38 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
67.27 |
Last 98 transactions |
Buy: 4 955 428 | Sell: 1 092 240 |
Volume Correlation
CytomX Therapeutics Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CytomX Therapeutics Inc Correlation - Currency/Commodity
CytomX Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $101.21M |
Gross Profit: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2023 |
Revenue: | $101.21M |
Gross Profit: | $99.04M (97.85 %) |
EPS: | $-0.00770 |
FY | 2022 |
Revenue: | $53.16M |
Gross Profit: | $47.31M (88.98 %) |
EPS: | $-1.480 |
FY | 2021 |
Revenue: | $69.57M |
Gross Profit: | $69.57M (100.00 %) |
EPS: | $-1.300 |
Financial Reports:
Symbol | Period | Year | Title |
---|---|---|---|
CTMX | Q1 | 2024 | Q1 2024 Financial Performance Analysis of CytomX Therapeutics Inc. |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators